About
Immunotherapies
Areas of Focus
Categories
DiagnosticsBiologics & BiopharmaceuticalSmall Molecule Pharmaceutical
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
482
By Phase
PHASE1/PHASE2: 3PHASE3: 1
By Status
RECRUITING: 2ENROLLING_BY_INVITATION: 1COMPLETED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06471673Lead Sponsor
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
PHASE1/PHASE2Recruiting
18 participants
Started: May 29, 2024 · Completed: Oct 30, 2025
NCT06072612Lead Sponsor
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
PHASE3Recruiting
404 participants
Started: Dec 5, 2023 · Completed: Jun 30, 2026
NCT03328026Lead Sponsor
Combination Study of SV-BR-1-GM With Retifanlimab
PHASE1/PHASE2Enrolling by invitation
36 participants
Started: Mar 16, 2018 · Completed: Nov 30, 2028
NCT03066947Lead Sponsor
SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
PHASE1/PHASE2Completed
24 participants
Started: May 5, 2017 · Completed: Nov 22, 2018
Locations (1)
Headquarters
West Vancouver, BC, Canada
Map
Loading map...